| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514110600 | Oxytocin or derivative | 16 |
| 20100279935 | COMPOSITIONS FOR INDUCING LABOR AND ASSOCIATED METHODS - The invention discloses a pharmaceutical composition containing oxytocin and melatonin in amounts therapeutically effective for inducing labor in a pregnant human patient. Preferably, the oxytocin content is reduced to mitigate unwanted side effects and the melatonin content synergistically enhances the oxytocin's labor-inducing effectiveness. Also disclosed is a pharmaceutical composition for treatment of a pregnant human patient experiencing pre-term labor characterized by early expression of melatonin receptors in myometrial cells, the composition containing one or more agents which interfere with melatonin binding to said receptors. Additionally, the invention includes a method of treatment effective in inducing labor in a pregnant human patient, the method comprising coadministering melatonin and oxytocin to the patient and a method of treating pre-term labor in a pregnant human patient manifesting early expression of melatonin receptors in her myometrial tissues, the method comprising administering to the patient an agent effective in blocking melatonin binding to the receptors. | 11-04-2010 |
| 20120028898 | METHODS FOR TREATMENT OF HEADACHES BY ADMINISTRATION OF OXYTOCIN - The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia. | 02-02-2012 |
| 20120172304 | INTRANASAL CARBETOCIN FORMULATIONS AND METHODS FOR THE TREATMENT OF AUTISM - Methods and compositions containing oxytocin or an oxytocin analog, such as carbetocin, are provided for the prevention and treatment of autism spectrum disorders, related disorders and symptoms of such disorders. The methods and compositions of this disclosure are effective in the treatment of social withdrawal, eye contact avoidance, repetitive behaviors, anxiety, attention deficit, hyperactivity, depression, loss of speech, verbal communication difficulties, aversion to touch, visual difficulties, comprehension difficulties, and sound and light sensitivity. Additional compositions and methods are provided which employ oxytocin or an oxytocin analog in combination with a secondary or adjunctive therapeutic agent to yield more effective treatment tools against autism spectrum disorders and related disorders. | 07-05-2012 |
| 20120178686 | CHEMICAL INDUCTION OF LACTATION - The present invention describes a method of inducing lactation in non-human mammals by using a single administrations of an estrogen compound, a dopaminergic antagonist, and oxytocin. For example, the estrogen compound may be a long acting composition and is administered at least one week before the dopaminergic antagonist. However, the oxytocin administration may be given the day after the dopaminergic antagonist, after which lactation may begin immediately. Preferred compounds may comprise a non-17β estradiol and domperidone. Such an injection protocol has resulted in the production of commercially viable volumes of milk from transgenic pigs. | 07-12-2012 |
| 20120270785 | Therapy and Prevention of Problem Drinking - The present invention provides methods for the therapy and prevention of problem drinking in alcohol-dependent and non-dependent subjects and those at risk of developing problem drinking behavior, and compositions of matter comprising oxytocin or an analog or derivative thereof or an agonist or partial agonist of an oxytocin receptor that are useful in preventing or treating problem drinking. | 10-25-2012 |
| 20120322736 | METHODS FOR TREATMENT OF HEADACHES BY ADMINISTRATION OF OXYTOCIN - The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia. | 12-20-2012 |
| 20130085106 | METHODS AND FORMULATIONS FOR OXYTOCIN TREATMENT OF SUBSTANCE USE, PSYCHIATRIC AND OTHER DISORDERS - The invention provides a method of treating a psychiatric or medical disorder in a mammalian subject, the method comprising administering to the subject an effective amount of an oxytocin receptor agonist (e.g., oxytocin). Optionally, the oxytocin receptor agonist is delivered by intranasal administration. Further provided is a method of increasing social cognition, increasing social functioning, increasing empathy, increasing trust of others, reducing paranoia and/or reducing hostility in a subject with a psychotic disorder, a mood disorder characterized by psychotic features, a personality disorder or a pervasive developmental disorder, the method comprising administering to the subject an effective amount of an oxytocin receptor agonist. The invention also contemplates a method of preventing opioid dependence, opioid tolerance and/or opioid withdrawal symptoms in a subject receiving opioid treatment for pain relief, the method comprising administering to the subject an effective amount of an oxytocin receptor agonist. The invention also provides pharmaceutical compositions comprising an effective amount of an oxytocin receptor agonist and a pharmaceutically acceptable carrier. | 04-04-2013 |
| 20130130985 | OXYTOCIN PEPTIDE ANALOGUES - Peptide analogues of oxytocin are described together with methods of treating conditions ameliorated by modulating oxytocin receptor. The peptide analogues are seleno or telluro peptide analogues. Methods of synthesis of selenocysteine, tellurocysteine and oxytocin analogues are also described. | 05-23-2013 |
| 20140018295 | NASAL DELIVERY - A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders. | 01-16-2014 |
| 20140171369 | Pharmaceutical Composition - The present invention relates to a novel pharmaceutical composition comprising oxytocin and/or one or more fragment(s) and/or variant(s) thereof and at least one non-ionic cellulose ether, such as hydroxypropylmethylcellulose, said pharmaceutical composition having a low pH. The present pharmaceutical composition has been shown to provide an exceptionally suitable environment for oxytocin, as the stability thereof has increased significantly as compared to previous compositions with this molecule. The pharmaceutical composition according to the invention can be used for medical purposes, such as in the treatment of climacteric disorders. | 06-19-2014 |
| 20150057226 | METHOD FOR TREATMENT OF LABOR ARREST - The present invention refers to the use of certain sulfated glycosaminoglycans for treatment of labor arrest. The sulfated glycosaminoglycans have a reduced anticoagulant activity and are administered in combination with an agent capable of promoting myometrial contractions of the uterus and thereby re-establish effective labor. | 02-26-2015 |
| 20150099703 | TREATMENT OF POSTPARTUM HAEMORRHAGE WITH CHEMICALLY MODIFIED HEPARIN OR HEPARAN SULPHATE AND A UTEROTONIC AGENT - The present invention refers to the use of certain sulfated glycosaminoglycans for treatment or prevention of postpartum haemorrhage. The sulfated glycosaminoglycans have a reduced anticoagulant activity and are administered in combination with at least one uterotonic agent capable of promoting myometrial contractions of the uterus and thereby compress the vessels and cease the bleeding. | 04-09-2015 |
| 20160058830 | Therapy and Prevention of Problem Drinking - The present invention provides methods for the therapy and prevention of problem drinking in alcohol-dependent and non-dependent subjects and those at risk of developing problem drinking behavior, and compositions of matter comprising oxytocin or an analog or derivative thereof or an agonist or partial agonist of an oxytocin receptor that are useful in preventing or treating problem drinking. | 03-03-2016 |
| 20160158156 | HEAT-STABLE DRY POWDER PHARMACEUTICAL COMPOSITIONS AND METHODS - Disclosed herein are heat-stable dry powders which include peptides or protein such as oxytocin for use as a pharmaceutical composition. The composition is highly stable at increased temperatures and relatively high humid environments, and are intended for storage at room temperature with an improved shelf-life. In particular, the dry powders are intended for inhalation, however, other routes of administration can be used when reconstituted in solution. | 06-09-2016 |
| 20160193282 | MAGNESIUM-CONTAINING OXYTOCIN FORMULATIONS AND METHODS OF USE | 07-07-2016 |
| 20170232059 | COMPOSITION COMPRISING OXYTOCIN | 08-17-2017 |
